Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction - PubMed (original) (raw)

Clinical Trial

Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction

Deepak Cyril D'Souza et al. Biol Psychiatry. 2005.

Abstract

Background: Recent advances in the neurobiology of cannabinoids have renewed interest in the association between cannabis and psychotic disorders.

Methods: In a 3-day, double-blind, randomized, placebo-controlled study, the behavioral, cognitive, motor, and endocrine effects of 0 mg, 2.5 mg, and 5 mg intravenous Delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 13 stable, antipsychotic-treated schizophrenia patients. These data were compared with effects in healthy subjects reported elsewhere.

Results: Delta-9-tetrahydrocannabinol transiently increased 1) learning and recall deficits; 2) positive, negative, and general schizophrenia symptoms; 3) perceptual alterations; 4) akathisia, rigidity, and dyskinesia; 5) deficits in vigilance; and 6) plasma prolactin and cortisol. Schizophrenia patients were more vulnerable to Delta-9-THC effects on recall relative to control subjects. There were no serious short- or long-term adverse events associated with study participation.

Conclusions: Delta-9-tetrahydrocannabinol is associated with transient exacerbation in core psychotic and cognitive deficits in schizophrenia. These data do not provide a reason to explain why schizophrenia patients use or misuse cannabis. Furthermore, Delta-9-THC might differentially affect schizophrenia patients relative to control subjects. Finally, the enhanced sensitivity to the cognitive effects of Delta-9-THC warrants further study into whether brain cannabinoid receptor dysfunction contributes to the pathophysiology of the cognitive deficits associated with schizophrenia.

PubMed Disclaimer

Cited by

Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.
Englund A, Oliver D, Chesney E, Chester L, Wilson J, Sovi S, De Micheli A, Hodsoll J, Fusar-Poli P, Strang J, Murray RM, Freeman TP, McGuire P. Englund A, et al. Neuropsychopharmacology. 2023 May;48(6):869-876. doi: 10.1038/s41386-022-01478-z. Epub 2022 Nov 16. Neuropsychopharmacology. 2023. PMID: 36380220 Free PMC article. Clinical Trial.
Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment.
Mondelli V, Dazzan P, Hepgul N, Di Forti M, Aas M, D'Albenzio A, Di Nicola M, Fisher H, Handley R, Marques TR, Morgan C, Navari S, Taylor H, Papadopoulos A, Aitchison KJ, Murray RM, Pariante CM. Mondelli V, et al. Schizophr Res. 2010 Feb;116(2-3):234-42. doi: 10.1016/j.schres.2009.08.013. Epub 2009 Sep 13. Schizophr Res. 2010. PMID: 19751968 Free PMC article.
The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia.
Krystal JH, D'Souza DC, Gallinat J, Driesen N, Abi-Dargham A, Petrakis I, Heinz A, Pearlson G. Krystal JH, et al. Neurotox Res. 2006 Dec;10(3-4):235-52. doi: 10.1007/BF03033360. Neurotox Res. 2006. PMID: 17197373 Review.
Efficient assessment of the time course of perceptual sensitivity change.
Zhao Y, Lesmes L, Lu ZL. Zhao Y, et al. Vision Res. 2019 Jan;154:21-43. doi: 10.1016/j.visres.2018.10.009. Epub 2018 Nov 12. Vision Res. 2019. PMID: 30389389 Free PMC article.
Correspondence on Curran et al. (2018): 'Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects'.
Vadhan NP, Corcoran CM, Keilp JG, Haney M. Vadhan NP, et al. Psychol Med. 2019 May;49(7):1227-1228. doi: 10.1017/S0033291718004178. Epub 2019 Jan 29. Psychol Med. 2019. PMID: 30691542 Free PMC article. No abstract available.

Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction - PubMed (original) (raw)